Force Matters: Biomechanical Regulation of Cell Invasion and Migration in Disease

Trends in Cell Biology

Volumn 26, Issue 7, 2016, Pages 486-497

  Kai, FuiBoon ^a   Laklai, Hanane ^a   Weaver, Valerie M ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Cardiovascular disease; Extracellular matrix stiffness; Fibrosis; Invasion; Migration

Indexed keywords

INTEGRIN;

ATHEROSCLEROSIS; BIOMECHANICS; CELL ADHESION; CELL DENSITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL MOTION; CHEMOTAXIS; DISEASE COURSE; EXTRACELLULAR MATRIX; FORCE; IN VITRO STUDY; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MECHANOTRANSDUCTION; NONHUMAN; ORGANOGENESIS; PODOSOME; PRIORITY JOURNAL; REVIEW; RIGIDITY; ANIMAL; DISEASES; HUMAN; METABOLISM; PATHOLOGY; TUMOR INVASION;

ANIMALS; BIOMECHANICAL PHENOMENA; CELL MOVEMENT; DISEASE; EXTRACELLULAR MATRIX; HUMANS; NEOPLASM INVASIVENESS; PODOSOMES;

EID: 84962030299     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2016.03.007     Document Type: Review

References (104)

1. Mouw J.K., et al. Extracellular matrix assembly: a multiscale deconstruction. Nat. Rev. Mol. Cell Biol. 2014, 15:771-785.
2. Bonnans C., et al. Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 2014, 15:786-801.
3. Boyd N.F., et al. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res. 2011, 13:223.
4. El-Serag H.B. Hepatocellular carcinoma. N. Engl. J. Med. 2011, 365:1118-1127.
5. Weber K.T., et al. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat. Rev. Cardiol. 2013, 10:15-26.
6. Rockey D.C., et al. Fibrosis--a common pathway to organ injury and failure. N. Engl. J. Med. 2015, 372:1138-1149.
7. Kim J.H., et al. Matrix cross-linking-mediated mechanotransduction promotes posttraumatic osteoarthritis. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:9424-9429.
8. Pellicoro A., et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat. Rev. Immunol. 2014, 14:181-194.
9. Ruffell B., et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 2014, 26:623-637.
10. Seneviratne A., et al. Biomechanical factors and macrophages in plaque stability. Cardiovasc. Res. 2013, 99:284-293.
11. Wilson M.S., Wynn T.A. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2009, 2:103-121.
12. Linder S., et al. Degrading devices: invadosomes in proteolytic cell invasion. Annu. Rev. Cell Dev. Biol. 2011, 27:185-211.
13. Petrie R.J., Yamada K.M. At the leading edge of three-dimensional cell migration. J. Cell Sci. 2012, 125:5917-5926.
14. Kothapalli D., et al. Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene expression and arterial stiffening. Cell Rep. 2012, 2:1259-1271.
15. Levental K.R., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
16. Acerbi I., et al. Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr. Biol. 2015, 7:1120-1134.
17. Mahadevan D., Von Hoff D.D. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol. Cancer Ther. 2007, 6:1186-1197.
18. Barron D.A., Rowley D.R. The reactive stroma microenvironment and prostate cancer progression. Endoc. Relat. Cancer 2012, 19:R187-R204.
19. Katsuda S., et al. Collagens in human atherosclerosis. Immunohistochemical analysis using collagen type-specific antibodies. Arterioscler. Thromb. 1992, 12:494-502.
20. Le T.T., et al. Label-free molecular imaging of atherosclerotic lesions using multimodal nonlinear optical microscopy. J. Biomed. Opt. 2007, 12:054007.
21. Alcolado R., et al. Pathogenesis of liver fibrosis. Clin. Sci. 1997, 92:103-112.
22. Frantz C., et al. The extracellular matrix at a glance. J. Cell Sci. 2010, 123:4195-4200.
23. Miller B.W., et al. Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Mol. Med. 2015, 7:1063-1076.
24. Pickup M.W., et al. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-beta-deficient mouse mammary carcinomas. Cancer Res. 2013, 73:5336-5346.
25. Pelham R.J., Wang Y. Cell locomotion and focal adhesions are regulated by substrate flexibility. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:13661-13665.
26. Isenberg B.C., et al. Vascular smooth muscle cell durotaxis depends on substrate stiffness gradient strength. Biophy. J. 2009, 97:1313-1322.
27. Prager-Khoutorsky M., et al. Fibroblast polarization is a matrix-rigidity-dependent process controlled by focal adhesion mechanosensing. Nat. Cell Biol. 2011, 13:1457-1465.
28. Lang N.R., et al. Biphasic response of cell invasion to matrix stiffness in three-dimensional biopolymer networks. Acta Biomater. 2015, 13:61-67.
29. Pathak A., Kumar S. Independent regulation of tumor cell migration by matrix stiffness and confinement. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:10334-10339.
30. Cassereau L., et al. A 3D tension bioreactor platform to study the interplay between ECM stiffness and tumor phenotype. J. Biotechnol. 2015, 193:66-69.
31. Rubashkin M.G., et al. Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phosphatidylinositol (3,4,5)-triphosphate. Cancer Res. 2014, 74:4597-4611.
32. Haage A., Schneider I.C. Cellular contractility and extracellular matrix stiffness regulate matrix metalloproteinase activity in pancreatic cancer cells. FASEB J. 2014, 28:3589-3599.
33. Wolf K., et al. Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J. Cell Biol. 2013, 201:1069-1084.
34. Miroshnikova Y.A., et al. Engineering strategies to recapitulate epithelial morphogenesis within synthetic three-dimensional extracellular matrix with tunable mechanical properties. Phys. Biol. 2011, 8:026013.
35. Plotnikov S.V., et al. Force fluctuations within focal adhesions mediate ECM-rigidity sensing to guide directed cell migration. Cell 2012, 151:1513-1527.
36. Gray D.S., et al. Repositioning of cells by mechanotaxis on surfaces with micropatterned Young's modulus. J. Biomed. Mater. Res. Part A 2003, 66:605-614.
37. Vincent L.G., et al. Mesenchymal stem cell durotaxis depends on substrate stiffness gradient strength. Biotechnol. J. 2013, 8:472-484.
38. Albiges-Rizo C., et al. Actin machinery and mechanosensitivity in invadopodia, podosomes and focal adhesions. J. Cell Sci. 2009, 122:3037-3049.
39. Hagedorn E.J., et al. The netrin receptor DCC focuses invadopodia-driven basement membrane transmigration in vivo. J. Cell Biol. 2013, 201:903-913.
40. Yamaguchi H., et al. Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J. Cell Biol. 2005, 168:441-452.
41. Yu X., et al. N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. J. Cell Biol. 2012, 199:527-544.
42. Gligorijevic B., et al. N-WASP-mediated invadopodium formation is involved in intravasation and lung metastasis of mammary tumors. J. Cell Sci. 2012, 125:724-734.
43. Leong H.S., et al. Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. Cell Rep. 2014, 8:1558-1570.
44. Euteneuer U., Schliwa M. Persistent, directional motility of cells and cytoplasmic fragments in the absence of microtubules. Nature 1984, 310:58-61.
45. Johnson H.E., et al. F-actin bundles direct the initiation and orientation of lamellipodia through adhesion-based signaling. J. Cell Biol. 2015, 208:443-455.
46. Wu C., et al. Arp2/3 is critical for lamellipodia and response to extracellular matrix cues but is dispensable for chemotaxis. Cell 2012, 148:973-987.
47. Collin O., et al. Spatiotemporal dynamics of actin-rich adhesion microdomains: influence of substrate flexibility. J. Cell Sci. 2006, 119:1914-1925.
48. Alexander N.R., et al. Extracellular matrix rigidity promotes invadopodia activity. Curr. Biol. 2008, 18:1295-1299.
49. Labernadie A., et al. Protrusion force microscopy reveals oscillatory force generation and mechanosensing activity of human macrophage podosomes. Nat. Commun. 2014, 5:5343.
50. Parekh A., et al. Sensing and modulation of invadopodia across a wide range of rigidities. Biophys. J. 2011, 100:573-582.
51. Carman C.V., et al. Transcellular diapedesis is initiated by invasive podosomes. Immunity 2007, 26:784-797.
52. Collin O., et al. Self-organized podosomes are dynamic mechanosensors. Curr. Biol. 2008, 18:1288-1294.
53. Paszek M.J., et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254.
54. Yeung T., et al. Effects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion. Cell Motil. Cytoskeleton 2005, 60:24-34.
55. Giannone G., et al. Periodic lamellipodial contractions correlate with rearward actin waves. Cell 2004, 116:431-443.
56. Giannone G., et al. Lamellipodial actin mechanically links myosin activity with adhesion-site formation. Cell 2007, 128:561-575.
57. Wong S., et al. Fibroblasts probe substrate rigidity with filopodia extensions before occupying an area. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:17176-17181.
58. Patsialou A., et al. Intravital multiphoton imaging reveals multicellular streaming as a crucial component of in vivo cell migration in human breast tumors. Intravital 2013, 2:e25294.
59. Gawden-Bone C., et al. A crucial role for beta2 integrins in podosome formation, dynamics and Toll-like-receptor-signaled disassembly in dendritic cells. J. Cell Sci. 2014, 127:4213-4224.
60. Destaing O., et al. beta1A integrin is a master regulator of invadosome organization and function. Mol. Biol. Cell 2010, 21:4108-4119.
61. Choma D.P., et al. Integrin alpha3beta1 directs the stabilization of a polarized lamellipodium in epithelial cells through activation of Rac1. J. Cell Sci. 2004, 117:3947-3959.
62. Rabinovitz I., Mercurio A.M. The integrin alpha6beta4 functions in carcinoma cell migration on laminin-1 by mediating the formation and stabilization of actin-containing motility structures. J. Cell Biol. 1997, 139:1873-1884.
63. Dumbauld D.W., et al. How vinculin regulates force transmission. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:9788-9793.
64. Lawson C., et al. FAK promotes recruitment of talin to nascent adhesions to control cell motility. J. Cell Biol. 2012, 196:223-232.
65. Spuul P., et al. Importance of RhoGTPases in formation, characteristics, and functions of invadosomes. Small GTPases 2014, 5:e28195.
66. Sit S.T., Manser E. Rho GTPases and their role in organizing the actin cytoskeleton. J. Cell Sci. 2011, 124:679-683.
67. Hoshino D., et al. Signaling inputs to invadopodia and podosomes. J. Cell Sci. 2013, 126:2979-2989.
68. Huveneers S., Danen E.H. Adhesion signaling - crosstalk between integrins, Src and Rho. J. Cell Sci. 2009, 122:1059-1069.
69. Ridley A.J., et al. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992, 70:401-410.
70. Jerrell R.J., Parekh A. Cellular traction stresses mediate extracellular matrix degradation by invadopodia. Acta Biomater. 2014, 10:1886-1896.
71. Parsons J.T., et al. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat. Rev. Mol. Cell Biol. 2010, 11:633-643.
72. Osiak A.E., et al. Subconfluent endothelial cells form podosomes downstream of cytokine and RhoGTPase signaling. Exp. Cell Res. 2005, 307:342-353.
73. Varon C., et al. Transforming growth factor beta induces rosettes of podosomes in primary aortic endothelial cells. Mol. Cell. Biol. 2006, 26:3582-3594.
74. Quintavalle M., et al. MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J. Cell Biol. 2010, 189:13-22.
75. Burgstaller G., Gimona M. Podosome-mediated matrix resorption and cell motility in vascular smooth muscle cells. Am. J. Physiol. 2005, 288:H3001-H3005.
76. Brown X.Q., et al. Effect of substrate stiffness and PDGF on the behavior of vascular smooth muscle cells: implications for atherosclerosis. J. Cell. Physiol. 2010, 225:115-122.
77. Edlund S., et al. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol. Biol. Cell 2002, 13:902-914.
78. Harms B.D., et al. Directional persistence of EGF-induced cell migration is associated with stabilization of lamellipodial protrusions. Biophys. J. 2005, 88:1479-1488.
79. Baker A.M., et al. Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK. Oncogene 2013, 32:1863-1868.
80. Huynh J., et al. Substrate stiffness regulates PDGF-induced circular dorsal ruffle formation through MLCK. Cell. Mol. Bioeng. 2013, 6:138-147.
81. Schrader J., et al. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology 2011, 53:1192-1205.
82. Akhurst R.J., Hata A. Targeting the TGFbeta signalling pathway in disease. Nat. Rev. Drug Discov. 2012, 11:790-811.
83. Connolly E.C., et al. Complexities of TGF-beta targeted cancer therapy. Int. J. Biol. Sci. 2012, 8:964-978.
84. King T.E., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014, 370:2083-2092.
85. Spond J., et al. Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulm. Pharmacol. Ther. 2003, 16:207-214.
86. Kagan H.M. Intra- and extracellular enzymes of collagen biosynthesis as biological and chemical targets in the control of fibrosis. Acta Tropica 2000, 77:147-152.
87. Luo Y., et al. A novel profibrotic mechanism mediated by TGFbeta-stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells. J. Pathol. 2015, 236:384-394.
88. Xiao Q., Ge G. Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. Cancer Microenviron. 2012, 5:261-273.
89. Kumar S., Weaver V.M. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 2009, 28:113-127.
90. Cox T.R., et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 2015, 522:106-110.
91. Contente S., et al. Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science 1990, 249:796-798.
92. Min C., et al. The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer. Cancer Res. 2007, 67:1105-1112.
93. Saika S., et al. Effect of fibrostatin C, an inhibitor of prolyl 4-hydroxylase, on collagen secretion by human Tenon's capsule fibroblasts in vitro. Graefe's Arch. Clin. Exp. Ophthalmol. 1996, 234(Suppl. 1):S214-S222.
94. Golubovskaya V.M. Targeting FAK in human cancer: from finding to first clinical trials. Front. Biosci. 2014, 19:687-706.
95. Olson M.F. Applications for ROCK kinase inhibition. Curr. Opin. Cell Biol. 2008, 20:242-248.
96. Kleikers P.W., et al. NADPH oxidases as a source of oxidative stress and molecular target in ischemia/reperfusion injury. J. Mol. Med. 2012, 90:1391-1406.
97. Maher B.M., et al. Statins alter neutrophil migration by modulating cellular Rho activity--a potential mechanism for statins-mediated pleotropic effects?. J. Leukocyte Biol. 2009, 85:186-193.
98. Chauhan V.P., et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 2013, 4:2516.
99. Keizman D., et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur. J. Cancer 2011, 47:1955-1961.
100. Zhao Y., et al. Ang II-AT1R increases cell migration through PI3K/AKT and NF-kappaB pathways in breast cancer. J. Cell. Physiol. 2014, 229:1855-1862.
101. Mair M., et al. JAK-STAT signaling in hepatic fibrosis. Front. Biosci. 2011, 16:2794-2811.
102. Gritsina G., et al. Targeted blockade of JAK/STAT3 signaling inhibits ovarian carcinoma growth. Mol. Cancer Ther. 2015, 14:1035-1047.
103. Quintas-Cardama A., et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115:3109-3117.
104. Sanz-Moreno V., et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell 2011, 20:229-245.